A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.

Living in an economically disadvantaged neighborhood is likely to lead to death at an earlier age, especially among African-Americans, new research shows. The death rate is even more pronounced among disadvantaged individuals with unhealthy lifestyle habits.

Amanda Mathis, chief financial officer of Bridgestone Americas, was just 35 when she first felt a lump in her right breast.

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.